A systemic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancer

Recent studies have shown the combination of Creactive protein (CRP) and albumin (The modified Glasgow Prognostic Score, mGPS) had prognostic value in some solid tumors. However, no studies have examined its prognostic role in small-cell lung cancer (SCLC) patients. In this retrospective study, 460 consecutive SCLC patients were screened. Eligible patient was assigned a mGPS of 0, 1, or 2 based on pre-treatment plasma CRP and albumin (0: CRP <= 10 mg/L; 1: CRP >10 mg/L and albumin >= 35 g/L; 2: CRP>10 mg/L and albumin<35 g/L). Univariate and multivariate analyses were performed to assess the prognostic value of relevant factors for SCLC. A total of 359 patients were analyzed. The mGPS of 0, 1, and 2 was assigned to 66.3, 30.6, and 3.1% of total patients. For patients with mGPS of 0, 1, and 2, median overall survival (OS) was 30.4, 28.2, and 14.3 months, respectively (P<0.001). Performance status (P<0.001), disease stage (P<0.001) and pre-treatment LDH (P<0.001) also significantly predicted OS. Multivariate analyses showed mGPS was an independent prognostic factor (P<0.001). This study demonstrated that higher mGPS independently predicts worse OS for SCLC patients. The assessment of mGPS could assist the identification of patients with poor prognosis and be a hierarchical factor in the future SCLC clinical trials.